Next Article in Journal
Isotretinoin and Thalidomide Down-Regulate c-MYC Gene Expression and Modify Proteins Associated with Cancer in Hepatic Cells
Next Article in Special Issue
Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed Synthesis of UDCA-Monoglyceride
Previous Article in Journal
Elucidation of the Structure of Lignin–Carbohydrate Complexes in Ginkgo CW-DHP by 13C-2H Dual Isotope Tracer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 19
10.3390/molecules26195741
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats

by
Devesh S. Agarwal
1,
Samrat Mazumdar
2,
Kishan S. Italiya
2,
Deepak Chitkara
2 and
Rajeev Sakhuja
1,*
1
Department of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, India
2
Department of Pharmacy, Birla Institute of Technology and Science, Pilani 333 031, India
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(19), 5741; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26195741
Submission received: 28 July 2021 / Revised: 17 September 2021 / Accepted: 17 September 2021 / Published: 22 September 2021
(This article belongs to the Special Issue Frontiers in Bile Acid Chemistry and Applications)
Browse Figures
Versions Notes

Abstract

:
A library of bile-acid-appended triazolyl aryl ketones was synthesized and characterized by detailed spectroscopic techniques such as 1H and 13C NMR, HRMS and HPLC. All the synthesized conjugates were evaluated for their cytotoxicity at 10 µM against MCF-7 (human breast adenocarcinoma) and 4T1 (mouse mammary carcinoma) cells. In vitro cytotoxicity studies on the synthesized conjugates against MCF-7 and 4T1 cells indicated one of the conjugate 6cf to be most active against both cancer cell lines, with IC50 values of 5.71 µM and 8.71 µM, respectively, as compared to the reference drug docetaxel, possessing IC50 values of 9.46 µM and 13.85 µM, respectively. Interestingly, another compound 6af (IC50 = 2.61 µM) was found to possess pronounced anticancer activity as compared to the reference drug docetaxel (IC50 = 9.46 µM) against MCF-7. In addition, the potent compounds (6cf and 6af) were found to be non-toxic to normal human embryonic kidney cell line (HEK 293), as evident from their cell viability of greater than 86%. Compound 6cf induces higher apoptosis in comparison to 6af (46.09% vs. 33.89%) in MCF-7 cells, while similar apoptotic potential was observed for 6cf and 6af in 4T1 cells. The pharmacokinetics of 6cf in Wistar rats showed an MRT of 8.47 h with a half-life of 5.63 h. Clearly, these results suggest 6cf to be a potential candidate for the development of anticancer agents.

Graphical Abstract

1. Introduction

Cancer is presently a major health concern around the globe, leading to an alarming increase in the number of deaths, after cardiovascular disease, which is further expected to elevate to 12 million by 2030, as per WHO report [1,2,3,4]. Among all, breast cancer is the second most treacherous and common form of malignant tumor found in 23% of all forms of female cancers [5,6]. Cancer treatment procedures, such as hormone and radiation therapy, immunotherapy, combination chemotherapy and surgery, have been implemented to achieve reasonable success in this battle of mankind against cancer [7]. Among these, chemotherapy has proved to be one of the most promising pathways to overcome cancer; however, concerns such as selectivity, resistance and bioavailability of existing chemotherapeutic agents and associated side effects limit its exemplification as an ideal cancer-treating procedure [8]. Thus, the search for selective anticancer agents with lower side effects and better efficacy remains a prime target of medicinal chemists around the globe.
In this realm, some of the endogenous steroids and secondary bile acids have proven their repute as valuable cytotoxic agents [9]. For example, tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) have shown significant apoptotic effects on various cancer cell lines [10,11,12,13]. Ursodeoxycholic acid (UDCA) has exhibited remarkable cytotoxicity against human oral squamous carcinoma (HSC-3), cultured animal/human tumor cells and HepG2 human hepatoma cells in combination with doxorubicin and also prevented colorectal adenoma recurrence [14,15]. Bile acids have also served as handy tools for the prodrug approach. For example, dihydroartemisinin–bile-acid hybridization has resulted in enhancement of dihydroartemisinin anticancer activity [16]. Strikingly, considerable research has been fueled toward developing steroidal heterocycles, in view of their broad spectrum of biological activities and added advantage of hydrophobic steroidal behavior capable of interacting with cell membranes [17].
In particular, 1,2,3-triazole provides favorable properties to binding molecular targets in a biological environment due to its metabolic stability and hydrogen-bonding capability [18]. Thus, the synthesis of diverse triazolyl steroids has received special interest due to a wide range of pharmacological properties such as anticancer [17,19] and antimicrobial [20,21]. Triazole-derived terpenoids/steroids such as oleanolic acid [22,23], betulinic acid [24,25,26,27,28], eteinic acid [29], nor-testosterone [30], androst-5-ene [31], estrone [29,32], 5α-androstane [33,34], cholesterol [20,21,35], 2-methoxyestradiol [36] and pregnenanes [37] have showcased interesting cytotoxic behavior against a variety of cancer cell lines (Figure 1, I–IV). However, bile-acid-appended triazoles have rarely been explored for their cytotoxic efficacy [38]. Drasar and coworkers documented one such report that discloses the synthesis and cytotoxicity of two ribbon-type pyridyl-based triazolyl cholic acid dimers, of which the ester analog demonstrated significant cytotoxic activity in low micromolar concentrations against lymphoblastic (CCRF-CEM) and myeloid leukemia (K562) cell lines (Figure 1, V) [29]. Perrone’s group reported cytotoxic studies on C-24-triazolyl-linked bile-acid–nucleoside conjugates, where a chenodeoxycholic-acid-linked deoxyadenosine derivative exhibited an IC50 value of 16.2 ± 2.2 µM against leukemia cell line (K562) (Figure 1, VI) [39]. The same group reported the synthesis of triazolyl-linked bile-acid–deoxyadenosine conjugates and evaluated their cytotoxic activity against two leukemia cell lines (Jurkat and K562), colon cancer cell line (HCT116), ovarian cancer cell line (A2780) and human fibroblast cell line. The best compound in this series exhibited an IC50 value of 8.51 ± 4.05 µM and 10.47 ± 2.64 µM against two leukemia cancer cell lines K562 and Jurkat, respectively (Figure 1, VII) [40].
In continuation to our program for the synthesis of C-24-functionalized bile acids as anticancer agents [41,42,43] and the aforementioned properties of triazolyl steroids, we present a synthetic approach for the synthesis of bile-acid-appended triazolyl aryl ketones. Their cytotoxic potency was examined against two breast cancer cell lines (MCF-7 and 4T1). In addition, in vivo pharmacokinetic study was also performed.

2. Results and Discussion

2.1. Chemistry

From the outset of the proposed work, the synthesis of targeted bile-acid-appended triazolyl aryl ketones commenced with the preparation of cholic acid and deoxycholic acid propargyl esters (4a,b) and amides (4c,d) by coupling cholic acid (1a)/deoxycholic acid (1b) with propargyl bromide (2)/propargyl amine hydrochloride (3), respectively, using reported single-step protocols (Scheme 1) [41,44]. Thereafter, a Cu-catalyzed multicomponent reaction between CA and DCA propargyl esters/amides (4a–d) with α-bromoacetophenones (5a–f) and sodium azide in aqueous DMF under microwave irradiation at 80 °C comfortably afforded the desired bile-acid-appended triazolyl aryl ketones (6aa–6df) in excellent yields (Scheme 1). All the synthesized compounds were completely characterized on the basis of 1H NMR, 13C NMR and HRMS. As a representative example, the assignment of hydrogen and carbons in 6aa was also performed using COSY, HSQC and HMBC (SI). The 1H and 13C NMR assignments for the representative proton/carbon signals of 6aa are given in Table 1, and selective correlations are showcased in Figure 2 on the basis of the 1H, 13C HMBC spectrum, please see Supplementary Materials.

2.2. Biological Evaluation

2.2.1. Cytotoxic Activity

All the synthesized compounds (6aa–df) were studied for their anticancer activity in two cancer lines viz. human breast adenocarcinoma (MCF-7) and mouse mammary carcinoma (4T1) cells at 10 µM concentration (Table 2). Most of the compounds showcased moderate-to-good activity against both cell lines as compared to the standard drug (docetaxel). Among all, compound 6af was found to be the most active (26.52% cell viability at 10 µM) against MCF-7 cells. In addition, compounds 6bf and 6cf were also found to be active against human breast cancer cell line (MCF-7), exhibiting cell viabilities of 44.43% and 37.53%, respectively, at 10 µM. In 4T1 cells, 6cf exhibited 49.27% cell viability at 10 µM. Triazolyl aryl ketones appended with cholic acid at the expense of an ester bond (6aa, 6ab, 6ac, 6ad, 6af) were found to be more active than their corresponding amide surrogates and deoxycholic acid ester/amide conjugates, except 6be and 6ce. In general, para-substitution (Me, OMe, F, Cl, Br) on the aryl ketone showcased lower cell viability as compared to the unsubstituted analogs. The analogs containing electron-withdrawing groups (F, Cl, Br) on aryl ketone were found to be more active as compared to the ones containing electron-donating groups (Me, OMe). Among halo-substituted analogs, triazolyl bromo-substituted aryl ketones appended to cholic acid and deoxycholic acid via an ester bond (6af, 6bf) and amide bond (6cf) were found to be more active in inhibiting the growth of MCF-7 cells. While in 4T1 cells, triazolyl bromo-substituted aryl ketones appended to cholic acid and deoxycholic acid via an amide bond (6cf, 6df) were found to be more active. In addition, adsorption, distribution, metabolism and excretion (ADME) properties and physiochemical properties of the synthesized analogs were calculated using molinspiration cheminformatics [45,46]. Additionally, percentage absorption and drug-likeness model score were also calculated using the reported formula [47] and Molsoft [48], respectively. As indicated by the TPSA values (between 60 and 160Å2), all the analogs (6aa–df) possessed better intestinal absorption ability over the blood–brain barrier (BBB) penetration power. Similarly, all the analogs (6aa–df) possessed a positive drug-likeness score between 0.60 and 1.14, indicating them to be ideal drug candidates. For instance, the most active analogs 6af, 6bf and 6cf were found to possess relatively good drug-likeness scores of 0.94, 0.85 and 0.88, respectively.
Further, all the compounds (6aa–df) tested on a normal human embryonic kidney cell line (HEK 293) indicated cell viability to be greater than 85% and thus were found to be non-toxic against normal cells (Table 2). In particular, the most active derivatives 6af, 6bf and 6cf possessing cell viability of 88.20, 86.82 and 87.82 appeared to be quite safer on normal human embryonic kidney cells.
IC50 values of the most potent compounds 6af, 6bf and 6cf were further evaluated against the two cancer cell lines by employing MTT assay (Table 3). Interestingly, 6af, 6bf and 6cf showed IC50 values in the range of 2.61–18.26 µM against the MCF-7 cancer cell line and 8.76–12.84 µM against the 4T1 cancer cell line. Compounds 6af (IC50 = 2.6 µM) and 6cf (IC50 = 5.71 µM) were found to possess pronounced anticancer activity as compared to the reference drug docetaxel (IC50 = 9.46 µM) against human breast adenocarcinoma (MCF-7), while all the three compounds (6af, 6bf, 6cf) were found to be more active with respect to docetaxel (IC50 = 13.85 µM) against rat mammary carcinoma (4T1). Further, these compounds did not induce cell death in HEK 293 cells.

2.2.2. Apoptotic Study

The apoptotic effect of 6af and 6cf was evaluated by the Annexin V/PI staining method. Following treatment of MCF-7 cells with 6af and 6cf at 2.61 µM and 5.71 µM, respectively, it was observed that compound 6cf was capable of inducing higher apoptosis in comparison to 6af (46.09% vs. 33.89%) (Figure 3a,b,e). Meanwhile, in 4T1 cells, both 6af (at 12.84 µM) and 6cf (at 8.76 µM) produced total apoptosis of 19.02% and 19.56%, indicating similar apoptotic potential in 4T1 cells (Figure 3c,d,e).
Of the two compounds, the most active compound 6cf was chosen for the in vivo pharmacokinetic study.

2.2.3. Pharmacokinetic Study of 6cf

The relationship between the pharmacokinetic parameters and in vitro cytotoxicity study could be useful in determining the starting dose for the initial clinical trials for anticancer drugs. The compound 6cf was found to have an IC50 (µM) of 5.71 and 8.76 µM in MCF-7 and 4T1 cells, respectively. The pharmacokinetic study was performed at a dose of 10 mg/kg i.v. bolus in rats that showed the initial concentration of 1752.69 ng/mL (~2.56 µM) with a half-life of 5.63 h. The mean plasma concentration–time profile of 6cf after a single dose of 10 mg/kg (intravenously) in rats is presented in Figure 4. Different pharmacokinetic parameters were evaluated by a non-compartmental model approach using Phoenix WinNonlin software as shown in Table 4. The initial concentration (C0) was found to be 1752.69 ± 66.52 ng/mL. The AUC0–last calculated based on the trapezoidal rule was found to be 1995.306 ± 87.43 ng.h/mL. The mean residence time (MRT) was found to be 8.47 ± 0.96 h. The 6cf half-life was found to be 5.63 ± 0.54 h [49]. Although it may not be feasible to predict the in vivo concentrations at the tumor site from the plasma concentrations, the pharmacokinetic data provide initial insights into the mean residence time of the drug candidate and may be useful in predicting the dose relationship with the pharmacological/toxic effect after in vivo assessment in the tumor models. Thus, further assessment in tumor models to advance this molecule is warranted.

3. Materials and Methods

All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), Alfa Aesar (Haverhill, MA, USA) and Spectrochem India Pvt. Ltd. (Mumbai, India) and used without further purification. The solvents were purchased from Merck (Burlington, MA, USA) and were distilled and dried before use. Nuclear magnetic resonance spectra were recorded on Bruker (Zurich, Switzerland) 400 spectrometer. The 1H NMR experiments were reported in δ units, parts per million (ppm), and were measured relative to residual chloroform (7.26 ppm) or DMSO-d6 (2.5 ppm) in the deuterated solvent. The 13C NMR spectra were reported in ppm relative to deuterochloroform (77.0 ppm) or DMSO-d6 (39.5 ppm). All coupling constants J were reported in Hz. The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, dd = doublet of doublet, m = multiplet and brs = broad singlet. Melting points were determined on a capillary point apparatus equipped with a digital thermometer and were uncorrected. Reactions were monitored by using thin-layer chromatography (TLC) on 0.2 mm silica gel F254 plates (Merck). The chemical structures of final products were confirmed by a high-resolution ESI/APCI hybrid quadrupole time-of-flight mass spectrometer. High-resolution mass spectrometry (HRMS) was performed with a Waters SYNAPT G2 HDMS instrument using time-of-flight (TOF-MS) with ESI/APCI- hybrid quadrupole. The purity of final products was confirmed by high-performance liquid chromatography (HPLC), using the following chromatographic conditions: liquid chromatographic conditions, a Thermo Fisher Rapid Separation (RS) UHPLC System (Ultimate 3000, Waltham, MA, USA) equipped with a pump (LPG-3400SD), Diode Array Detector (DAD) (DAD-3000, Thermo Fisher, Waltham, MA, USA) and autosampler (ACC-3000T, Thermo Fisher, Waltham, MA, USA) were used for purity analysis. The UHPLC system was equilibrated for approximately 40 min before beginning the sample analysis. Control of hardware and data handling was performed using Chromeleon software version 7.2 SR4 (Thermo Fisher, Waltham, MA, USA). Column: Inertsil® (GL Sciences, Tokyo, Japan) ODS C18 column (250 × 4.6 mm, 5µm). Mobile phase: ACN: water (95:05 % v/v); flow rate: 1 mL/min; detection wavelength: 259 nm; retention time: 3–5 min.

3.1. General Procedure for the Synthesis of CA and DCA Propargyl Amides (4c,d)

To a stirred solution of bile acid (CA (1a) or DCA (1b), 2.0 g, 1 equiv) in DMF (10 mL), triethyl amine (2.5 equiv) was added at 0 °C, and subsequently EDC.HCl (1.5 equiv) and HOBt (1 equiv) were added. The reaction mixture was stirred for 15 min at 0 °C, after which propargyl amine hydrochloride (1.5 equiv) was added. The reaction was stirred at room temperature for 6–8 h and was monitored by TLC. After the completion of the reaction, the reaction mixture was poured over crushed ice, and the resulted precipitate was filtered, washed with cold water, recrystallized from ethyl acetate/hexanes and triturated with diethyl ether to afford bile acid propargyl amide (4c,d), please see Supplementary Materials.
(4R)-N-(Prop-2-yn-1-yl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (4c): White solid; Yield: 90% (1.96 g); mp: 277–279 °C (Lit. [41] 276–278 °C); 1H NMR (400 MHz, DMSO-d6) δ 8.23 (t, J = 5.5 Hz, 1H, NHAmide), 4.36 (d, J = 4.3 Hz, 1H, OHCA), 4.13 (d, J = 3.5 Hz, 1H, OHCA), 4.04 (d, J = 3.4 Hz, 1H, OHCA), 3.82 (dd, J = 5.6, 2.5 Hz, 2H), 3.78 (d, J = 3.4 Hz, 1H, H-12CA), 3.64–3.57 (m, 1H, H-7CA), 3.24–3.14 (m, 1H, H-3CA), 3.08 (t, J = 2.5 Hz, 1H, CHAlkyne), 2.25–2.12 (m, 2H), 2.04–1.92 (m, 2H), 1.84–1.59 (m, 6H), 1.48–1.06 (m, 14H), 0.92 (d, J = 6.4 Hz, 3H, Me-21CA), 0.81 (s, 3H, Me-19CA), 0.58 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 172.9 (C=O), 81.9, 73.2, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 46.6, 46.2, 42.0, 41.8, 35.8, 35.6, 35.3, 34.9, 32.7, 32.0, 30.9, 29.0, 28.2, 27.8, 26.7, 23.3, 23.1 (C-19CA), 17.6 (C-21CA), 12.8 (C-18CA).
(4R)-4-((3R,10S,12S,13R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(prop-2-yn-1-yl)pentanamide (4d): White solid; Yield: 89% (1.94 g); mp: 182–184 °C (Lit. [41] 184–186 °C); 1H NMR (400 MHz, DMSO-d6) δ 8.23 (t, J = 5.5 Hz, 1H, NHAmide), 4.50 (brs, 1H, OHDCA), 4.22 (brs, 1H, OHDCA), 3.82 (dd, J = 5.6, 2.5 Hz, 2H), 3.79 (d, J = 2.7 Hz, 1H, H-12DCA), 3.47 (brs, 1H, H-3DCA), 3.09 (t, J = 2.5 Hz, 1H, CHAlkyne), 2.13–1.95 (m, 2H), 1.83–1.74 (m, 2H), 1.72–1.42 (m, 8H), 1.39–1.06 (m, 14H), 0.91 (d, J = 6.4 Hz, 3H, Me-21DCA), 0.85 (s, 3H, Me-19DCA), 0.59 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 172.8 (C=O), 81.9, 73.2, 71.5 (C-12DCA), 70.4 (C-3DCA), 47.9, 46.7, 46.4, 42.1, 36.7, 36.1, 35.6, 35.5, 34.3, 33.4, 32.6, 32.0, 30.7, 29.1, 28.2, 27.7, 27.4, 26.6, 24.0, 23.6 (C-19DCA), 17.5 (C-21DCA), 12.9 (C-18DCA).

3.2. General Procedure for the Synthesis of Bile-Acid-Appended Triazolyl Aryl Ketones (6aa–df)

Bile acid propargyl ester/propargyl amide (4a–d) (100 mg, 1 equiv), NaN3 (2 equiv), CuSO4.5H2O (0.05 equiv), sodium ascorbate (0.4 equiv) and substituted α-bromo acetone/phenacyl bromide (5a–f) (2 equiv) were added in a microwave vial containing DMF:H2O (4 mL:1 mL) mixture. The reaction mixture was stirred under microwave irradiation for 30 min at 80 °C, and the progress of the reaction was monitored by TLC (MeOH:DCM, 1% v/v). After the completion of the reaction, the mixture was quenched by adding crushed ice. The aqueous layer was extracted using ethyl acetate (2 × 20 mL). The combined organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure and subjected to flash column chromatography (SiO2 (100–200 mesh), DCM:MeOH, 99:1 v/v) to yield pure bile-acid-appended triazolyl aryl ketone (6aa–6df), please see Supplementary Materials.
(1-(2-Oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6aa): Off-white solid; Yield: 82% (0.111 g); mp: 108–109 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.11 (s, 1H, HTriazole), 8.10–8.03 (m, 2H, HAr), 7.80–7.70 (m, 1H, HAr), 7.66–7.58 (m, 2H, HAr), 6.20 (s, 2H), 5.18 (s, 2H), 4.33 (d, J = 4.3 Hz, 1H, OHCA), 4.12 (d, J = 3.8 Hz, 1H, OHCA), 4.01 (d, J = 3.3 Hz, 1H, OHCA), 3.78 (d, J = 3.8 Hz, 1H, H-12CA), 3.61 (brs, 1H, H-7CA), 3.17 (d, J = 5.1 Hz, 1H, H-3CA), 2.43–2.27 (m, 2H), 2.23–2.13 (m, 2H), 1.97–1.63 (m, 7H), 1.47–1.12 (m, 13H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.80 (s, 3H, Me-19CA), 0.57 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 192.5 (C=O), 173.6 (C=O), 142.4, 134.7, 134.6, 129.5, 128.6, 126.9, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.3, 46.6, 46.2, 42.0, 41.8, 35.8, 35.5, 35.3, 34.9, 31.1, 30.9, 29.0, 27.7, 26.7, 23.1 (C-19CA), 17.4 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula C35H50N3O6+ 608.3694: found: 608.3685; Anal. RP-HPLC tR = 3.773 min, purity 95.46%; [ α ] D 20 = +20 (c 1.0, MeOH).
(1-(2-Oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6ba): Off-white solid; Yield: 87% (0.119 g); mp: 143–144 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.11 (s, 1H, HTriazole), 8.07 (d, J = 7.9 Hz, 2H, HAr), 7.75 (t, J = 7.4 Hz, 1H, HAr), 7.65–7.57 (d, J = 7.5 Hz, 2H, HAr), 6.20 (s, 2H), 5.17 (s, 2H), 4.53 (d, J = 4.2 Hz, 1H, OHDCA), 4.24 (d, J = 3.9 Hz, 1H, OHDCA), 3.78 (brs, 1H, H-12DCA), 3.49 (brs, 1H, H-3DCA), 2.46–2.30 (m, 2H), 2.25–2.13 (m, 2H), 1.74–1.44 (m, 9H), 1.37–1.14 (m, 13H), 0.90 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.84 (s, 3H, Me-19DCA), 0.57 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 192.6 (C=O), 173.6 (C=O), 142.3, 134.7, 134.5, 129.5, 128.6, 126.9, 71.5 (C-12DCA), 70.4 (C-3DCA), 57.5, 56.3, 47.9, 46.6, 46.5, 42.1, 36.7, 36.1, 35.6, 35.4, 34.3, 33.4, 31.1, 30.7, 29.0, 27.6, 27.4, 26.6, 23.6 (C-19DCA), 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula C35H50N3O5+ 592.3745 found: 592.3733; Anal. RP-HPLC tR = 4.553 min, purity 94.55%; [ α ] D 20 = +16 (c 1.0, MeOH).
(4R)-N-((1-(2-Oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6ca): Off-white solid; Yield: 83% (0.112 g); mp: 148–149 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (t, J = 5.8 Hz, 1H, NHAmide), 8.09–8.05 (m, 2H, HAr), 7.84 (s, 1H, HTriazole), 7.77–7.72 (m, 1H, HAr), 7.61 (t, J = 7.7 Hz, 2H, HAr), 6.15 (s, 2H), 4.39 (brs, 1H, OHCA), 4.33 (d, J = 5.7 Hz, 2H), 4.12 (d, J = 3.7 Hz, 1H, OHCA), 4.03 (d, J = 3.5 Hz, 1H, OHCA), 3.78 (d, J = 3.8 Hz, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.18 (s, 1H, H-3CA), 2.19–2.10 (m, 2H), 2.05 – 1.94 (m, 2H), 1.80–1.60 (m, 6H), 1.49–1.15 (m, 14H), 0.93 (d, J = 6.1 Hz, 3H, Me-21CA), 0.79 (s, 3H, Me-19CA), 0.56 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 192.7 (C=O), 173.2 (C=O), 145.6, 134.7, 134.6, 129.5, 128.6, 124.9, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.2, 54.7, 46.6, 46.2, 41.9, 41.8, 35.6, 35.3, 34.8, 34.6, 32.1, 30.8, 29.0, 27.8, 26.7, 23.1 (C-19CA), 17.6 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H51N4O5+ 607.3854 found: 607.3840; Anal. RP-HPLC tR = 3.780 min, purity 95.86%; [ α ] D 20 = +58 (c 1.0, MeOH).
(4R)-4-((3R,10S,12S,13R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-((1-(2-oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)methyl)pentanamide (6da): Off-white solid; Yield: 80% (0.110 g); mp: 135–136 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (t, J = 5.7 Hz, 1H, NHAmide), 8.06 (d, J = 7.1 Hz, 2H, HAr), 7.84 (s, 1H, HTriazole), 7.74 (t, J = 7.4 Hz, 1H, HAr), 7.61 (t, J = 7.7 Hz, 2H, HAr), 6.15 (s, 2H), 4.53 (d, J = 4.2 Hz, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.22 (d, J = 4.0 Hz, 1H, OHDCA), 3.78 (brs, 1H, H-12DCA), 3.48 (brs, 1H, H-3DCA), 2.17–1.98 (m, 2H), 1.76–1.44 (m, 10H), 1.37–1.14 (m, 14H), 0.91 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.56 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 192.7 (C=O), 173.1 (C=O), 145.6, 134.7, 134.6, 129.4, 128.6, 124.8, 71.5 (C-12DCA), 70.4 (C-3DCA), 56.2, 47.9, 46.7, 46.4, 42.1, 36.7, 36.1, 35.6, 35.5, 34.6, 34.3, 33.4, 32.8, 32.1, 30.7, 29.1, 27.7, 27.4, 26.6, 24.0, 23.6 (C-19DCA), 17.5 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H51N4O4+ 591.3905 found: 591.3883; Anal. RP-HPLC tR = 3.610 min, purity 96.50%; [ α ] D 20 = +9 (c 1.0, MeOH).
(1-(2-Oxo-2-(p-tolyl)ethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6ab): White solid; Yield: 76% (0.103 g); mp: 121–124 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 7.97 (d, J = 8.3 Hz, 2H, HAr), 7.42 (d, J = 8.0 Hz, 2H, HAr), 6.15 (s, 2H), 5.16 (s, 2H), 4.38 (d, J = 4.4 Hz, 1H, OHCA), 4.15 (d, J = 3.5 Hz, 1H, OHCA), 4.05 (d, J = 3.3 Hz, 1H, OHCA), 3.77 (d, J = 3.4 Hz, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.21–3.14 (m, 1H, H-3CA), 2.42 (s, 3H, MeAr), 2.30–2.18 (m, 2H), 2.14–1.92 (m, 2H), 1.84–1.55 (m, 8H), 1.45–1.66 (m, 12H), 0.91 (d, J = 6.1 Hz, 3H, Me-21CA), 0.79 (s, 3H, Me-19CA), 0.56 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 192.0 (C=O), 173.6 (C=O), 145.3, 142.3, 132.0, 130.0, 128.7, 126.9, 71.4 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.2, 46.5, 46.2, 42.0, 41.8, 35.4, 35.3, 34.8, 31.1, 31.0, 30.8, 29.0, 27.7, 26.6, 23.1 (C-19CA), 21.8 (MeAr), 17.3 (C-21CA), 12.8 (C-18CA); Anal. RP-HPLC tR = 4.010 min, purity 99.37%; HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H52N3O6+ 622.3851 found: 622.3837; [ α ] D 20 = +29 (c 1.0, MeOH).
(1-(2-Oxo-2-(p-tolyl)ethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6bb): White solid; Yield: 79% (0.110 g); mp: 123–125 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 7.97 (d, J = 8.2 Hz, 2H, HAr), 7.42 (d, J = 8.0 Hz, 2H, HAr), 6.15 (s, 2H), 5.16 (s, 2H), 4.53 (d, J = 4.3 Hz, 1H, OHDCA), 4.24 (d, J = 4.1 Hz, 1H, OHDCA), 3.78 (d, J = 3.8 Hz, 1H, H-12DCA), 3.47 (brs, 1H, H-3DCA), 2.42 (s, 3H, MeAr), 2.39–2.24 (m, 2H), 1.85–1.50 (m, 10H), 1.47–1.15 (m, 14H), 0.90 (d, J = 6.2 Hz, 3H, Me-21DCA), 0.83 (s, 3H, Me-19DCA), 0.57 (s, 3H, Me-18DCA);13C NMR (100 MHz, DMSO-d6) δ 192.0 (C=O), 173.6 (C=O), 145.3, 142.3, 132.0, 130.0, 128.7, 126.9, 71.5 (C-12DCA), 70.4 (C-3DCA), 57.5, 56.2, 47.9, 46.6, 46.5, 42.0, 36.7, 36.1, 35.6, 35.4, 34.3, 33.4, 31.1, 30.7, 29.0, 27.6, 27.4, 26.6, 24.0, 23.5 (C-19DCA), 21.8, 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M]+ calcd for chemical formula: C36H52N3O5+ 606.3901 found: 606.3874; Anal. RP-HPLC tR = 4.813 min, purity 95.99% [ α ] D 20 = +47 (c 1.0, MeOH).
(4R)-N-((1-(2-Oxo-2-(p-tolyl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6cb): White solid; Yield: 77% (0.107 g); mp: 129–131 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (t, J = 5.7 Hz, 1H, NHAmide), 7.96 (d, J = 8.2 Hz, 2H, HAr), 7.82 (s, 1H, HTriazole), 7.41 (d, J = 8.1 Hz, 2H, HAr), 6.11 (s, 2H), 4.38 (d, J = 4.3 Hz, 1H, OHCA), 4.32 (d, J = 5.7 Hz, 2H), 4.13 (d, J = 3.5 Hz, 1H, OHCA), 4.04 (d, J = 3.3 Hz, 1H, OHCA), 3.77 (d, J = 3.6 Hz, 1H, H-12CA), 3.59 (brs, 1H, H-7CA), 3.23–3.16 (m, 1H, H-3CA), 2.41 (s, 3H, MeAr), 2.22–2.11 (m, 2H), 2.06–1.94 (m, 2H), 1.82–1.58 (m, 7H), 1.50–1.11 (m, 13H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.78 (s, 3H, Me-19CA), 0.55 (s, 3H, Me-18CA);13C NMR (100 MHz, DMSO-d6) δ 192.1 (C=O), 173.2 (C=O), 145.6, 145.3, 132.1, 130.0, 128.7, 124.8, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.1, 46.6, 46.2, 42.0, 41.8, 35.8, 35.6, 35.3, 34.8, 34.6, 32.8, 32.1, 30.8, 29.0, 27.8, 26.7, 23.1 (C-19CA), 21.7 (MeAr), 17.6 (C-21CA), 12.8 (C-18CA);HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H53N4O5+ 621.4010 found: 621.4006; Anal. RP-HPLC tR = 3.770 min, purity 95.06%; [ α ] D 20 = +19 (c 1.0, MeOH).
(4R)-4-((3R,10S,12S,13R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-((1-(2-oxo-2-(p-tolyl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)pentanamide (6db): White solid Yield: 80% (0.112 g); mp: 112–115 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.37 (t, J = 5.8 Hz, 1H, NHAmide), 7.97 (d, J = 8.2 Hz, 2H, HAr), 7.82 (s, 1H, HTriazole), 7.41 (d, J = 8.1 Hz, 2H, HAr), 6.11 (s, 2H), 4.48 (d, J = 4.2 Hz, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.20 (d, J = 4.1 Hz, 1H, OHDCA), 3.77 (d, J = 3.8 Hz, 1H, H-12DCA), 3.37 (brs, 1H, H-3DCA), 2.42 (s, 3H, MeAr), 2.15–1.95 (m, 2H), 1.82–1.42 (m, 11H), 1.37–1.13 (m, 13H), 0.92 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.56 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 192.1 (C=O), 173.0 (C=O), 145.6, 145.2, 132.1, 130.0, 128.7, 124.8, 71.5 (C-12DCA), 70.4 (C-3DCA), 56.1, 47.9, 46.7, 46.4, 42.1, 36.1, 35.5, 34.6, 34.3, 33.4, 32.8, 32.1, 29.1, 27.7, 27.4, 26.6, 24.0, 23.5 (C-19DCA), 21.8 (MeAr), 17.5 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H53N4O4+ 605.4035 found: 605.4061; Anal. RP-HPLC tR = 4.100 min, purity 93.82%; [ α ] D 20 = +(c 1.0, MeOH).
(1-(2-(4-Methoxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6ac): Off-white solid; Yield: 80% (0.114 g); mp: 176–177 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 8.05 (d, J = 8.9 Hz, 2H, 2H, HAr), 7.13 (d, J = 9.0 Hz, 2H, HAr), 6.13 (s, 2H), 5.17 (s, 2H), 4.36 (brs, 1H, OHCA), 4.14 (d, J = 3.5 Hz, 1H, OHCA), 4.04 (d, J = 3.3 Hz, 1H, OHCA), 3.88 (s, 3H, OMeAr), 3.77 (d, J = 3.1 Hz, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.22–3.15 (m, 1H, H-3CA), 2.40–2.24 (m, 2H), 2.23–2.10 (m, 2H), 1.80–1.61 (m, 6H), 1.49–1.09 (m, 14H), 0.91 (d, J = 6.1 Hz, 3H, Me-21CA), 0.80 (s, 3H, Me-19CA), 0.57 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 190.8 (C=O), 173.6 (C=O), 164.4, 142.3, 131.1, 127.4, 126.9, 114.7, 71.4 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.2, 55.9, 46.5, 46.2, 42.0, 41.8, 35.8, 35.5, 35.3, 34.8, 31.1, 31.0, 30.9, 29.0, 27.7, 26.7, 23.3, 23.1 (C-19CA), 17.4 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H52N3O7+ 638.3800 found: 638.3798; Anal. RP-HPLC tR = 4.003 min, purity 99.43%; [ α ] D 20 = +31 (c 1.0, MeOH).
(1-(2-(4-Methoxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6bc): Off-white solid; Yield: 81% (0.116 g); mp: 144–45 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.09 (s, 1H, HTriazole), 8.05 (d, J = 8.8 Hz, 2H, HAr), 7.13 (d, J = 8.9 Hz, 2H, HAr), 6.12 (s, 2H), 5.17 (s, 2H), 4.52 (d, J = 4.3 Hz, 1H, OHDCA), 4.22 (d, J = 4.1 Hz, 1H, OHDCA), 3.88 (s, 3H, OMeAr), 3.78 (d, J = 4.2 Hz, 1H, H-12DCA), 3.46 (brs, 1H, H-3DCA), 2.43–2.31 (m, 2H), 2.29–2.15 (m, 2H), 1.78–1.55 (m, 10H), 1.35–1.20 (m, 12H), 0.91 (d, J = 6.2 Hz, 3H, Me-21DCA), 0.84 (s, 3H, Me-19 DCA), 0.57 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 190.8 (C=O), 173.6 (C=O), 164.4, 142.3, 131.1, 127.4, 126.9, 114.7, 71.5 (C-12DCA), 70.5 (C-3DCA), 57.5, 56.2, 55.9, 47.9, 46.6, 46.5, 42.0, 36.7, 36.1, 35.6, 35.4, 34.3, 33.4, 31.0, 30.7, 29.0, 27.6, 27.4, 26.5, 23.5 (C-19DCA), 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H52N3O6+ 622.3851 found: 622.3853; Anal. RP-HPLC tR = 4.797 min, purity 97.61%; [ α ] D 20 = +11 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Methoxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6cc): Off-white solid; Yield: 81% (0.115 g); mp: 158–159 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.38 (t, J = 5.8 Hz, 1H, NHAmide), 8.04 (d, J = 8.9 Hz, 2H, HAr), 7.82 (s, 1H, HTriazole), 7.12 (d, J = 9.0 Hz, 2H, HAr), 6.08 (s, 2H), 4.36 (brs, 1H, OHCA), 4.34–4.29 (m, 2H), 4.12 (d, J = 3.5 Hz, 1H, OHCA), 4.03 (d, J = 3.5 Hz, 1H, OHCA), 3.87 (s, 3H, OMeAr), 3.77 (d, J = 3.5 Hz, 1H, H-12CA), 3.59 (brs, 1H, H-7CA), 3.22–3.16 (m, 1H, H-3CA), 2.20–2.13 (m, 2H), 2.04–1.95 (m, 2H), 1.81–1.63 (m, 6H), 1.48–1.29 (m, 8H), 1.27–1.17 (m, 6H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.78 (s, 3H, Me-19CA), 0.55 (s, 3H, Me-18CA);13C NMR (100 MHz, DMSO-d6) δ 190.9 (C=O), 173.1 (C=O), 164.3, 145.6, 131.0, 127.5, 124.8, 114.7, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.2, 55.8, 46.6, 46.2, 42.0, 41.8, 35.8, 35.6, 35.3, 34.8, 34.6, 32.1, 30.9, 29.0, 27.8, 26.7, 23.3, 23.1 (C-19CA), 17.5 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H53N4O6+ 637.3960 found: 637.3961; Anal. RP-HPLC tR = 4.097 min, purity 93.92%; [ α ] D 20 = +47 (c 1.0, MeOH).
(4R)-4-((3R,10S,12S,13R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-((1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)pentanamide (6dc): Off-white solid; Yield: 76% (0.109 g); mp: 114–115 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.38 (t, J = 5.7 Hz, 1H, NHAmide), 8.05 (d, J = 8.9 Hz, 2H, HAr), 7.82 (s, 1H, HTriazole), 7.12 (d, J = 9.0 Hz, 2H, HAr), 6.08 (s, 2H), 4.51–4.49 (m, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.21 (d, J = 4.1 Hz, 1H, OHDCA), 3.88 (s, 3H, OMeAr), 3.78 (d, J = 4.0 Hz, 1H, H-12DCA), 3.40 (brs, 1H, H-3DCA), 2.01–2.03 (m, 2H), 2.00–1.80 (d, J = 8.3 Hz, 2H), 1.77–1.47 (m, 10H), 1.–1.18 (m, 12H), 0.92 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.56 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 190.9 (C=O), 173.1 (C=O), 164.3, 145.6, 131.0, 127.5, 124.8, 114.7, 71.5 (C-12DCA), 70.4 (C-3DCA), 56.2, 55.8, 47.9, 46.7, 46.4, 42.1, 36.7, 36.1, 35.6, 35.5, 34.6, 34.3, 33.4, 32.8, 32.1, 30.7, 29.1, 27.7, 27.4, 26.6, 23.5 (C-19DCA), 17.5 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C36H53N4O5+ 621.4010 found: 621.4009; Anal. RP-HPLC tR = 4.097 min, purity 94.90%; [ α ] D 20 = +21 (c 1.0, MeOH).
(1-(2-(4-Fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6ad): Off-white solid; Yield: 76% (0.106 g); mp: 152–153 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.19–8.09 (m, 3H, HTriazole&HAr), 7.46 (t, J = 8.7 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.35 (d, J = 4.3 Hz, 1H, OHCA), 4.13 (d, J = 3.4 Hz, 1H, OHCA), 4.03 (d, J = 3.7 Hz, 1H, OHCA), 3.77 (brs, 1H, H-12CA), 3.61 (brs, 1H, H-7CA), 3.22–3.16 (m, 1H, H-3CA), 2.41–2.24 (m, 2H), 2.21–2.14 (m, 2H), 1.83–1.67 (m, 5H), 1.64–1.40 (m, 5H), 1.35–1.17 (m, 10H), 0.91 (d, J = 5.9 Hz, 3H, Me-21CA), 0.80 (s, 3H, Me-19CA), 0.57 (s, 3H, Me-18CA);13C NMR (100 MHz, DMSO-d6) δ 191.3 (C=O), 173.6 (C=O), 142.4, 131.8, 132.7, 126.9, 116.7, 116.5, 71.4 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.2, 46.5, 46.2, 42.0, 35.8, 35.5, 35.3, 34.8, 31.1, 31.1, 30.9, 29.0, 27.7, 26.7, 23.3, 23.1 (C-19CA), 17.4 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O6F+ 626.3600 found: 626.3600; Anal. RP-HPLC tR = 3.783 min, purity 95.12%; [ α ] D 20 = +51 (c 1.0, MeOH).
(1-(2-(4-Fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6bd): Off-white solid; Yield: 72% (0.101 g); mp: 127–128 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.19–8.14 (m, 2H, HAr), 8.10 (s, 1H, HTriazole), 7.46 (t, J = 8.9 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.49 (d, J = 4.3 Hz, 1H, OHDCA), 4.22 (d, J = 4.0 Hz, 1H, OHDCA), 3.78 (d, J = 4.1 Hz, 1H, H-12DCA), 3.43–3.40 (m, 1H, H-3DCA), 2.40–2.22 (m, 2H), 1.81–1.70 (m, 5H), 1.62–1.44 (m, 5H), 1.36–1.11 (m, 14H), 0.91 (d, J = 6.1 Hz, 3H, Me-21DCA), 0.84 (s, 3H, Me-19DCA), 0.57 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 191.3 (C=O), 173.6 (C=O), 142.4, 131.8, 131.7, 126.9, 116.7, 116.5, 71.5 (C-12DCA), 70.4 (C-3DCA), 57.5, 56.2, 47.9, 46.6, 46.5, 42.1, 36.7, 36.1, 35.6, 35.4, 34.3, 33.4, 31.1, 30.7, 29.0, 27.6, 27.4, 26.6, 24.0, 23.6 (C-19DCA), 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O5F+ 610.3651 found: 610.3650; Anal. RP-HPLC tR = 5.333 min, purity 96.72%; [ α ] D 20 = +8 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6cd): Off-white solid; Yield: 79% (0.110 g); mp: 137–138 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.40 (t, J = 5.7 Hz, 1H, NHAmide), 8.15 (dd, J = 8.8, 5.5 Hz, 2H, HAr), 7.83 (s, 1H, HTriazole), 7.45 (t, J = 8.9 Hz, 2H, HAr), 6.15 (s, 2H), 4.44 (brs, 1H, OHCA), 4.32 (d, J = 5.7 Hz, 2H), 4.14 (brs, 1H, OHCA), 4.06–4.01 (m, 1H, OHCA), 3.77 (d, J = 3.0 Hz, 1H, H-12CA), 3.61–3.58 (m, 1H, H-7CA), 3.21–3.16 (m, 1H, H-3CA), 2.16–2.12 (m, 2H), 2.03–1.99 (m, 2H), 1.80–1.60 (m, 7H), 1.44–1.12 (m, 13H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.78 (s, 3H, Me-19CA), 0.55 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 191.4 (C=O), 173.2 (C=O), 145.7, 131.8, 131.7, 124.8, 116.7, 116.4, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.1, 46.6, 46.2, 42.0, 41.8, 35.8, 35.6, 35.3, 34.8, 34.6, 32.8, 32.1, 30.8, 29.0, 27.8, 26.7, 23.1 (C-19CA), 17.6 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O5F+ 625.3760 found: 625.3754; Anal. RP-HPLC tR = 4.000 min, purity 94.54%; [ α ] D 20 = +22 (c 1.0, MeOH).
(4R)-4-((3R,10S,12S,13R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-((1-(2-(4-fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)pentanamide (6dd): Off-white solid; Yield: 77% (0.117 g); mp: 126–127 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.40–8.36 (m, 1H, NHAmide), 8.18–8.14 (m, 2H, HAr), 7.83 (s, 1H, HTriazole), 7.46 (d, J = 8.8 Hz, 2H, HAr), 6.15 (s, 2H), 4.49 (d, J = 4.3 Hz, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.20 (d, J = 4.1 Hz, 1H, OHDCA), 3.77 (d, J = 3.8 Hz, 1H, H-12DCA), 3.43–3.40 (m, 1H, H-3DCA), 2.18 – 1.98 (m, 2H), 1.80–1.66 (m, 6H), 1.64–1.44 (m, 5H), 1.35–1.15 (m, 13H), 0.92 (d, J = 6.4 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.56 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 191.4 (C=O), 173.1 (C=O), 145.7, 131.8, 131.7, 124.8, 116.7, 116.4, 71.5 (C-12DCA), 70.4 (C-3DCA), 56.1, 47.9, 46.7, 46.4, 42.1, 36.7, 36.1, 35.6, 35.5, 34.6, 34.3, 33.4, 32.8, 32.1, 30.7, 29.1, 27.7, 27.4, 26.6, 24.0, 23.5 (C-19DCA), 17.5 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O4F+ 609.3811 found: 609.3807; Anal. RP-HPLC tR = 4.030 min, purity 95.47%; [ α ] D 20 = +60 (c 1.0, MeOH).
(1-(2-(4-Chlorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6ae): Off-white solid; Yield: 74% (0.106 g); mp: 153–154 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 8.08 (d, J = 8.6 Hz, 2H, HAr), 7.70 (d, J = 8.6 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.39 (brs, 1H, OHCA), 4.15 (d, J = 3.5 Hz, 1H, OHCA), 4.05 (d, J = 3.3 Hz, 1H, OHCA), 3.77 (d, J = 3.4 Hz, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.18 (brs, 1H, H-3CA), 2.42–2.24 (m, 2H), 2.22–2.09 (m, 2H), 1.82–1.59 (m, 7H), 1.49–1.14 (m, 13H), 0.91 (d, J = 6.1 Hz, 3H, Me-21CA), 0.80 (s, 3H, Me-19CA), 0.56 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 191.7 (C=O), 173.6 (C=O), 142.4, 139.6, 133.3, 130.6, 129.6, 126.8, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.3, 46.5, 46.2, 42.0, 41.8, 35.8, 35.4, 35.3, 34.8, 31.2, 31.1, 30.8, 29.0, 27.7, 26.7, 23.1 (C-19CA), 17.4 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O6Cl+ 642.3304 found: 642.3291; Anal. RP-HPLC tR = 4.107 min, purity 97.01%; [ α ] D 20 = +27 (c 1.0, MeOH).
(1-(2-(4-Chlorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6be): Off-white solid; Yield: 72% (0.104 g); mp: 92–93 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (d, J = 2.8 Hz, 2H, HAr), 8.07 (s, 1H, HTriazole), 7.69 (d, J = 8.6 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.52 (d, J = 4.2 Hz, 1H, OHDCA), 4.22 (d, J = 4.1 Hz, 1H, OHDCA), 3.78 (d, J = 3.7 Hz, 1H, H-12DCA), 3.48 (brs, 1H, H-3DCA), 2.43–2.15 (m, 2H), 1.82–1.43 (m, 11H), 1.37–1.08 (m, 13H), 0.90 (d, J = 6.2 Hz, 3H, Me-21DCA), 0.84 (s, 3H, Me-19DCA), 0.57 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 191.7 (C=O), 173.6 (C=O), 142.4, 139.6, 133.3, 130.6, 129.6, 126.9, 71.4 (C-12DCA), 70.4 (C-3DCA), 57.5, 56.3, 47.9, 46.6, 46.5, 42.0, 36.8, 36.1, 35.6, 35.4, 34.3, 33.4, 31.1, 31.1, 29.0, 27.6, 27.4, 26.6, 23.6 (C-19DCA), 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O5Cl+ 626.3355 found: 626.3336; Anal. RP-HPLC tR = 5.343 min, purity 96.73%; [ α ] D 20 = +18 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Chlorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6ce): Off-white solid; Yield: 78% (0.112 g); mp: 154–155 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.40 (t, J = 5.7 Hz, 1H, NHAmide), 8.07 (d, J = 8.6 Hz, 2H, HAr), 7.83 (s, 1H, HTriazole), 7.69 (d, J = 8.6 Hz, 2H, HAr), 6.15 (s, 2H), 4.39 (brs, 1H, OHCA), 4.32 (d, J = 5.7 Hz, 2H), 4.14 (brs, 1H, OHCA), 4.05 (brs, 1H, OHCA), 3.77 (brs, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.21–3.17 (m, 1H, H-3CA), 2.24–2.16 (m, 2H), 2.14–2.07 (m, 2H), 1.81–1.61 (m, 7H), 1.44–1.20 (m, 13H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.78 (s, 3H, Me-19CA), 0.54 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 191.8 (C=O), 173.2 (C=O), 145.7, 139.6, 133.3, 130.5, 129.6, 124.8, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.2, 46.6, 46.2, 42.0, 41.8, 35.8, 35.6, 35.3, 34.9, 34.8, 34.6, 32.8, 32.7, 32.1, 32.0, 30.8, 29.0, 28.2, 27.8, 23.3 (C-19CA), 17.5 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O5Cl+ 641.3464 found: 641.3457; Anal. RP-HPLC tR = 3.607 min, purity 97.57%; [ α ] D 20 = +16 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Chlorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6de): Off-white solid; Yield: 76% (0.110 g); mp: 100–101 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (t, J = 5.8 Hz, 1H, NHAmide), 8.07 (d, J = 8.6 Hz, 2H, HAr), 7.82 (s, 1H, HTriazole), 7.69 (d, J = 8.6 Hz, 2H, HAr), 6.15 (s, 2H), 4.52 (d, J = 4.1 Hz, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.22 (d, J = 4.2 Hz, 1H, OHDCA), 3.77 (brs, 1H, H-12DCA), 3.47 (m, 1H, H-3DCA), 2.20–2.09 (m, 2H), 2.05–1.98 (m, 2H), 1.78–1.51 (m, 11H), 1.35–1.18 (m, 11H), 0.91 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.55 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 192.0 (C=O), 172.9 (C=O), 145.7, 139.6, 133.3, 130.5, 129.6, 124.8, 71.5 (C-12DCA), 70.4 (C-3DCA), 56.2, 47.9, 46.7, 46.4, 42.1, 36.8, 36.1, 35.6, 35.5, 34.6, 34.3, 33.4, 32.8, 32.1, 30.7, 29.1, 27.7, 27.4, 26.6, 24.0, 23.5 (C-19DCA), 17.5 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O4Cl+ 625.3515 found: 625.3492; Anal. RP-HPLC tR = 4.040 min, purity 96.32%; [ α ] D 20 = +47 (c 1.0, MeOH).
(1-(2-(4-Bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6af): Off-white solid; Yield: 83% (0.127 g); mp: 159–160 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 8.00 (d, J = 8.6 Hz, 2H, HAr), 7.84 (d, J = 8.6 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.39 (d, J = 3.6 Hz, 1H, OHCA), 4.15 (d, J = 3.3 Hz, 1H, OHCA), 4.05 (d, J = 3.1 Hz, 1H, OHCA), 3.77 (brs, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.23–3.16 (m, 1H, H-3CA), 2.42–2.28 (m, 2H), 2.25–2.09 (m, 2H), 1.81–1.60 (m, 7H), 1.47–1.15 (m, 13H), 0.91 (d, J = 6.1 Hz, 3H, Me-21CA), 0.80 (s, 3H, Me-19CA), 0.56 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 191.9 (C=O), 173.6 (C=O), 142.4, 133.6, 132.5, 130.6, 128.9, 126.9, 71.4 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 57.5, 56.3, 46.5, 46.2, 42.0, 41.8, 35.8, 35.5, 35.3, 34.8, 31.1, 30.9, 29.0, 27.7, 26.7, 23.3, 23.1 (C-19CA), 17.3 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O6Br+ 686.2799 found: 686.2780; Anal. RP-HPLC tR = 4.197 min, purity 96.62%; [ α ] D 20 = +11 (c 1.0, MeOH).
(1-(2-(4-Bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl (4R)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (6bf): Off-white solid; Yield: 80% (0.124 g); mp: 176–177 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, HTriazole), 8.00 (d, J = 8.7 Hz, 2H, HAr), 7.84 (d, J = 8.6 Hz, 2H, HAr), 6.19 (s, 2H), 5.17 (s, 2H), 4.50 (d, J = 4.3 Hz, 1H, OHDCA), 4.23 (d, J = 4.1 Hz, 1H, OHDCA), 3.78 (d, J = 3.8 Hz, 1H, H-12DCA), 3.43 (brs, 1H, H-3DCA), 2.40–2.20 (m, 2H), 1.80–1.44 (m, 10H), 1.36–1.16 (m, 14H), 0.90 (d, J = 6.2 Hz, 3H, Me-21DCA), 0.84 (s, 3H, Me-19DCA), 0.57 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 191.9 (C=O), 173.6 (C=O), 142.4, 133.6, 132.5, 130.6, 128.9, 126.9, 71.5 (C-12DCA), 70.4 (C-3DCA), 57.5, 56.3, 47.9, 46.6, 46.5, 42.1, 36.7, 36.1, 35.6, 35.4, 34.3, 33.4, 33.1, 31.1, 30.7, 29.0, 27.6, 27.4, 26.6, 24.0, 23.6 (C-19DCA), 17.3 (C-21DCA), 12.9 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H49N3O5Br+ 670.2850 found: 670.2855; Anal. RP-HPLC tR = 5.507 min, purity 98.37%; [ α ] D 20 = +81 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6cf): Off-white solid; Yield: 81% (0.124 g); mp: 144–145 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (t, J = 5.8 Hz, 1H, NHAmide), 7.99 (d, J = 8.3 Hz, 2H, HAr), 7.86–7.81 (m, 3H, HTriazole&HAr), 6.15 (s, 2H), 4.36 (d, J = 4.3 Hz, 1H, OHCA), 4.32 (d, J = 5.7 Hz, 2H), 4.12 (d, J = 3.5 Hz, 1H, OHCA), 4.03 (d, J = 3.4 Hz, 1H, OHCA), 3.79–3.76 (m, 1H, H-12CA), 3.60 (brs, 1H, H-7CA), 3.21–3.15 (m, 1H, H-3CA), 2.18–2.12 (m, 2H), 2.04–1.94 (m, 2H), 1.83–1.58 (m, 8H), 1.50–1.15 (m, 12H), 0.92 (d, J = 6.2 Hz, 3H, Me-21CA), 0.78 (s, 3H, Me-19CA), 0.55 (s, 3H, Me-18CA); 13C NMR (100 MHz, DMSO-d6) δ 192.1 (C=O), 173.1 (C=O), 145.7, 133.6, 132.5, 130.6, 128.8, 124.8, 71.5 (C-12CA), 70.9 (C-3CA), 66.7 (C-7CA), 56.2, 46.6, 46.2, 42.0, 41.8, 35.6, 35.3, 34.8, 34.6, 32.8, 32.1, 30.9, 29.0, 27.8, 26.7, 23.3, 23.0 (C-19CA), 17.5 (C-21CA), 12.8 (C-18CA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O5Br+ 685.2959 found: 685.2956; Anal. RP-HPLC tR = 3.720 min, purity 96.70%; [ α ] D 20 = +13 (c 1.0, MeOH).
(4R)-N-((1-(2-(4-Bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-((3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (6df): Off-white solid; Yield: 79% (0.122 g); mp: 135–136 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.36 (t, J = 5.7 Hz, 1H, NHAmide), 7.99 (d, J = 8.6 Hz, 2H, HAr), 7.88–7.80 (m, 3H, HTriazole&HAr), 6.14 (s, 2H), 4.48 (d, J = 4.2 Hz, 1H, OHDCA), 4.32 (d, J = 5.7 Hz, 2H), 4.19 (d, J = 4.1 Hz, 1H, OHDCA), 3.78 (brs, 1H, H-12DCA), 3.39 (brs, 1H, H-3DCA), 2.15–2.00 (m, 2H), 1.77–1.47 (m, 11H), 1.36–1.16 (m, 13H), 0.91 (d, J = 6.3 Hz, 3H, Me-21DCA), 0.82 (s, 3H, Me-19DCA), 0.55 (s, 3H, Me-18DCA); 13C NMR (100 MHz, DMSO-d6) δ 192.1 (C=O), 173.2 (C=O), 145.7, 133.6, 132.5, 130.6, 128.8, 124.8, 71.5 (C-12DCA), 70.9 (C-3DCA), 56.2, 46.6, 46.2, 42.0, 41.8, 35.7, 35.6, 35.3, 34.8, 32.8, 30.8, 27.8, 26.7, 23.1 (C-19DCA), 17.5 (C-21DCA), 12.8 (C-18DCA); HRMS (ESI): m/z [M + H]+ calcd for chemical formula: C35H50N4O4Br+ 669.3010 found: 669.3003; Anal. RP-HPLC tR = 3.937 min, purity 98.65%; [ α ] D 20 = +17 (c 1.0, MeOH).

3.3. Biological Assay

3.3.1. Cell Culture and MTT Assay

The cytotoxicity activity of all the conjugates (6aa–6df) was evaluated in vitro by MTT assay against two different breast cancer cell lines 4T1 (murine) and MCF-7 (human) and HEK 293 (human) as normal cell line. DTX was used as positive control. Cells were grown in DMEM supplemented with 10% FBS and 1% antibiotic solution and incubated at 5% CO2 and 37 °C for 24 h. The stock solutions of all the conjugates were prepared in DMSO and diluted for further use. Briefly, 5 × 103 cells/well were seeded in 96-well cell culture plates and allowed to adhere for 24 h. Cell inhibition (%) was determined after 48 h exposure to the compounds at 1–25 μM concentration. After 48 h, MTT assay was performed and the yellow tetrazolium salt (MTT) was reduced in metabolically active cells to form insoluble purple formazan crystals, which were solubilized by the addition of DMSO. The optical density (OD) was recorded at 560 nm and 630 nm as reference wavelength. Percentage cell inhibition was determined by comparison with untreated cells [50,51].

3.3.2. Apoptotic Study

The extent of apoptosis induced by compounds 6af and 6cf in MCF-7 and 4T1 cells was quantified by flow cytometry according to the manufacturer’s protocol. Briefly, cells were seeded in a 6-well plate at a cell density of 1 × 106 cells/well. After 24 h, the media was discarded and cells were treated with fresh media containing compounds 6af and 6cf at their respective IC50 concentrations for 48 h. After treatment, cells were trypsinized, harvested in PBS and collected by centrifugation for 5 min at 2000 rpm. Cells were then resuspended in 1X binding buffer and stained with FITC-labeled Annexin V Alexa Fluor 488 (5 μL) and propidium iodide (10 μL). Cells were analyzed using flow cytometer (Beckman Coulter), and data were analyzed with CytExpert software.

3.3.3. Pharmacokinetic Study of 6cf

Wistar rats (male; 8–10 weeks, 200–240 g) were procured from Central Animal Facility, BITS Pilani (Pilani, India). Animal experiment protocol was approved by Institutional Animal Ethics Committee (IAEC/RES/24/03), BITS Pilani, Pilani, and all experiments were conducted as per CPCSEA guidelines. Rats were housed in well-ventilated cages at standard laboratory conditions with regular light/dark cycles for 12 h and fed with standard normal diet ab libitum.
The pharmacokinetic study of 6cf was performed on Wistar rats. 6cf solution (prepared in normal saline with 5% w/v tween 80) was administered intravenously at the dose of 10 mg/kg with maximum dosing volume of 300 µL to each rat without fasting (n = 4). After i.v. dosing, blood samples were collected for each preset time point at 10, 20, 30, 50 min, 1.5, 2, 4, 6, 8, 12 and 24 h. 6cf plasma concentration–time profile was plotted and analyzed by non-compartmental model approach using Phoenix 2.1 WinNonlin (Pharsight Corporation, USA) to determine t1/2, elimination half-life; C0, drug concentration in plasma at t = 0; AUC0-t, area under curve from zero to the last time point; AUC0–∞, area under curve from zero to infinity; and MRT, mean residence time.

3.3.4. Determination of 6cf in Rat Plasma

A simple liquid–liquid extraction (LLE) method was used for extraction of 6cf from the rat plasma. A 200 µL aliquot of plasma sample containing 6cf was taken in 5 mL glass tube, followed by the addition of 100 µL of internal standard (I.S.) (clobetasol, 2 µg/mL) solution. Samples were vortexed for 1 min, and then 2 mL of ethyl acetate was added as extracting solvent. The samples were vortexed for 5 min and centrifuged at 5000 rpm for 15 min at 4 °C. The organic layer was collected and evaporated to dryness at 40 ± 0.5 °C. The residue was reconstituted with 250 µL of mobile phase and vortexed for 1 min. Finally, 150 µL of sample was injected into HPLC for quantification.

3.3.5. Liquid Chromatographic Conditions

A Thermo Fisher Rapid Separation (RS) UHPLC System (Ultimate 3000) equipped with a pump (LPG-3400SD), Diode Array Detector (DAD) (DAD-3000) and autosampler (ACC-3000T) with 250 µL injection loop was used for purity analysis. The UHPLC system was equilibrated for approximately 40 min before beginning the sample analysis. Column temperature was 35° throughout the analysis. 6cf and I.S. were separated on Intersil® ODS (C18) column (250 × 4.6 mm, 5µm) with a mobile phase consisting of acetonitrile:water (60:40 % v/v) run in isocratic mode at a flow rate of 1 mL/min, detection wavelength 259 nm and injection volume of 150 µL. Retention time was found to be 6.2 and 12.2 min for 6cf and clobetasol (I.S.), respectively. Control of hardware and data handling was performed using Chromeleon software version 7.2 SR4.

4. Conclusions

In summary, we synthesized a series of cholic-acid- and deoxycholic-acid-appended triazolyl aryl ketones in excellent yields via a Cu-catalyzed multi-component approach. All the synthesized conjugates were evaluated for their cytotoxicity against human breast adenocarcinoma (MCF-7) and mouse mammary carcinoma (4T1) cells at 10 µM, which highlighted three conjugates (6af, 6bf, 6cf) displaying interesting anticancer activity with IC50 values less than 19 µM on both tested cancer cell lines. Among these, the cholic-acid-appended triazolyl 4-bromophenyl ketone (6cf) connected via an amide bond was found to be active against both cancer cell lines with IC50 values of 5.71 µM and 8.71 µM, respectively, as compared to the reference drug possessing an IC50 value of 9.46 µM and 13.85 µM, respectively. Meanwhile, cholic-acid-appended triazolyl 4-bromophenyl ketone connected via an ester bond (6af) was found to be active against both cancer cell lines with IC50 values of 2.61 µM and 12.84 µM, respectively. Most of the conjugates showed low cytotoxicity toward the normal human embryonic kidney cell line (HEK 293) as evident from their cell viability data. Apoptosis studies of 6af and 6cf on MCF-7 cells at their respective IC50 values indicated induction of higher apoptosis by 6cf in comparison to 6af (46.09% vs. 33.89%). Meanwhile, in 4T1 cells, a similar apoptotic potential of the two compounds contributing to a total apoptosis of 19.02% and 19.56% in 4T1 cells was observed. Additionally, an MRT of 8.47 h with a half-life of 5.63 h was observed by in vivo pharmacokinetics studies of 6cf in rats. In light of the present work, it appears that cytotoxicity is not only driven by the nature of the bile acid, but also by the electronic effect of the substituent present on the aryl moiety of aryl ketones. Clearly, the results suggest the potential of the studied conjugates in the development of anticancer drug candidates.

Supplementary Materials

Original 1H and 13C NMR spectra of 4c,d and 6aa–6df, COSY, HSQC and HMBC spectra of 6aa, HRMS spectra of 6aa–6df and HPLC chromatogram of 6aa–6df.

Author Contributions

Conceptualization, R.S.; methodology, D.S.A.; resources, R.S. and D.C.; data curation, D.S.A., S.M. and K.S.I.; writing—original draft preparation, D.S.A.; writing—review and editing, R.S. and D.C.; supervision, R.S. and D.C.; project administration, R.S. and D.C.; funding acquisition, R.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was approved by the Institutional Animal Ethics Committee (IAEC/RES/24/03), BITS Pilani, Pilani.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not Applicable.

Acknowledgments

Rajeev Sakhuja is thankful to CSIR (02(0391)21/EMR-II) for funding for this work. We would also like to thank the central NMR facility BITS Pilani. The authors also sincerely acknowledge financial support from DST under the FIST program (Project: SR/FST/CSI-270/2015) for the HRMS facility.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 6aa–df are available from the authors.

References

  1. Bach, P.B.; Jett, J.R.; Pastorino, U.; Tockman, M.S.; Swensen, S.J.; Begg, C.B. Computed tomography screening and lung cancer outcomes. Jama 2007, 297, 953–961. [Google Scholar] [CrossRef] [Green Version]
  2. Gibbs, J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287, 1969–1973. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Arve, L.; Voigt, T.; Waldmann, H. Charting biological and chemical space: PSSC and SCONP as guiding principles for the development of compound collections based on natural product scaffolds. Qsar Comb. Sci. 2006, 25, 449–456. [Google Scholar] [CrossRef] [Green Version]
  4. Gali, R.; Banothu, J.; Porika, M.; Velpula, R.; Hnamte, S.; Bavantula, R.; Abbagani, S.; Busi, S. Indolylmethylene benzo [h] thiazolo [2,3-b] quinazolinones: Synthesis, characterization and evaluation of anticancer and antimicrobial activities. Bioorg. Med. Chem. Lett. 2014, 24, 4239–4242. [Google Scholar] [CrossRef] [PubMed]
  5. Sørlie, T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur. J. Cancer 2004, 40, 2667–2675. [Google Scholar] [CrossRef] [PubMed]
  6. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Ca-Cancer J. Clin. 2011, 61, 212–236. [Google Scholar] [CrossRef] [PubMed]
  7. Chabner, B.A.; Roberts Jr, T.G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5, 65. [Google Scholar] [CrossRef]
  8. Rosen, H.; Abribat, T. The rise and rise of drug delivery. Nat. Rev. Drug Discov. 2005, 4, 381. [Google Scholar] [CrossRef]
  9. Kim, N.-D.; Im, E.-O.; Choi, Y.-H.; Yoo, Y.-H. Synthetic bile acids: Novel mediators of apoptosis. Bmb Rep. 2002, 35, 134–141. [Google Scholar] [CrossRef] [Green Version]
  10. Carey, E.J.; Lindor, K.D. Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons. Clin. Res. Hepatol. Gastroenterol. 2012, 36, S61–S64. [Google Scholar] [CrossRef]
  11. Serfaty, L.; Bissonnette, M.; Poupon, R. Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol. Clin. Biol. 2010, 34, 516–522. [Google Scholar] [CrossRef]
  12. Serfaty, L. Chemoprevention of colorectal cancer with ursodeoxycholic acid: Pro. Clin. Res. Hepatol. Gastroenterol. 2012, 36, S53–S60. [Google Scholar] [CrossRef]
  13. Tatsumura, T.; Sato, H.; Yamamoto, K.; Ueyama, T. Ursodeoxycholic acid prevents gastrointestinal disorders caused by anticancer drugs. Jpn. J. Surg. 1981, 11, 84–89. [Google Scholar] [CrossRef] [PubMed]
  14. Pang, L.; Zhao, X.; Liu, W.; Deng, J.; Tan, X.; Qiu, L. Anticancer effect of ursodeoxycholic acid in human oral squamous carcinoma HSC-3 cells through the caspases. Nutrients 2015, 7, 3200–3218. [Google Scholar] [CrossRef] [Green Version]
  15. Dyakova, L.; Culita, D.-C.; Marinescu, G.; Alexandrov, M.; Kalfin, R.; Patron, L.; Alexandrova, R. Metal Zn (II), Cu (II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents. Biotechnol. Biotechnol. Equip. 2014, 28, 543–551. [Google Scholar] [CrossRef]
  16. Marchesi, E.; Chinaglia, N.; Capobianco, M.L.; Marchetti, P.; Huang, T.-E.; Weng, H.-C.; Guh, J.-H.; Hsu, L.-C.; Perrone, D.; NavacchiaKomori, M.L. Dihydroartemisinin–bile acid hybridization as an effective approach to enhance dihydroartemisinin anticancer activity. ChemMedChem 2019, 14, 779–787. [Google Scholar] [CrossRef]
  17. Gupta, A.; Kumar, B.S.; Negi, A.S. Current status on development of steroids as anticancer agents. J. Steroid Biochem. Mol. Biol. 2013, 137, 242–270. [Google Scholar] [CrossRef] [PubMed]
  18. Agalave, S.G.; Maujan, S.R.; Pore, V.S. Click chemistry: 1,2,3-triazoles as pharmacophores. Chem. Asian J. 2011, 6, 2696–2718. [Google Scholar] [CrossRef]
  19. Frank, E.; Molnar, J.; Zupko, I.; Kadar, Z.; Wolfling, J. Synthesis of novel steroidal 17α-triazolyl derivatives via Cu (I)-catalyzed azide-alkyne cycloaddition, and an evaluation of their cytotoxic activity in vitro. Steroids 2011, 76, 1141–1148. [Google Scholar] [CrossRef] [Green Version]
  20. Aly, M.R.E.S.; Saad, H.A.; Mohamed, M.A.M. Click reaction based synthesis, antimicrobial, and cytotoxic activities of new 1,2,3-triazoles. Bioorg. Med. Chem. Lett. 2015, 25, 2824–2830. [Google Scholar] [CrossRef]
  21. Aly, M.R.E.S.; Saad, H.A.; Abdel-Hafez, S.H. Synthesis, antimicrobial and cytotoxicity evaluation of new cholesterol congeners. Beilstein J. Org. Chem. 2015, 11, 1922–1932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Pertino, M.; Lopez, C.; Theoduloz, C. Schmeda-Hirschmann, G. 1,2,3-Triazole-substituted oleanolic acid derivatives: Synthesis and antiproliferative activity. Molecules 2013, 18, 7661–7674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Wei, G.; Luan, W.; Wang, S.; Cui, S.; Li, F.; Liu, Y.; Liu, Y.; Cheng, M. A library of 1,2,3-triazole-substituted oleanolic acid derivatives as anticancer agents: Design, synthesis, and biological evaluation. Org. Biomol. Chem. 2015, 13, 1507–1514. [Google Scholar] [CrossRef]
  24. Bębenek, E.; Kadela-Tomanek, M.; Chrobak, E.; Latocha, M.; Boryczka, S. Novel triazoles of 3-acetylbetulin and betulone as anticancer agents. Med. Chem. Res. 2018, 27, 2051–2061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Majeed, R.; Sangwan, P.L.; Chinthakindi, P.K.; Khan, I.; Dangroo, N.A.; Thota, N.; Hamid, A.; Sharma, P.R.; Saxena, A.K.; Koul, S. Synthesis of 3-O-propargylated betulinic acid and its 1, 2, 3-triazoles as potential apoptotic agents. Eur. J. Med. Chem. 2013, 63, 782–792. [Google Scholar] [CrossRef]
  26. Sidova, V.; Zoufaly, P.; Pokorny, J.; Dzubak, P.; Hajduch, M.; Popa, I.; Urban, M. Cytotoxic conjugates of betulinic acid and substituted triazoles prepared by Huisgen Cycloaddition from 30-azidoderivatives. PLoS ONE 2017, 12, e0171621. [Google Scholar] [CrossRef] [Green Version]
  27. Csuk, R.; Barthel, A.; Kluge, R.; Strohl, D. Synthesis, cytotoxicity and liposome preparation of 28-acetylenic betulin derivatives. Bioorg. Med. Chem. 2010, 18, 7252–7259. [Google Scholar] [CrossRef]
  28. Csuk, R.; Barthel, A.; Sczepek, R.; Siewert, B.; Schwarz, S. Synthesis, encapsulation and antitumor activity of new betulin derivatives. Arch. Pharm. 2011, 344, 37–49. [Google Scholar] [CrossRef]
  29. Jurášek, M.; Džubák, P.; Sedlák, D.; Dvořáková, H.; Hajdúch, M.; Bartůněk, P.; Drašar, P. Preparation, preliminary screening of new types of steroid conjugates and their activities on steroid receptors. Steroids 2013, 78, 356–361. [Google Scholar] [CrossRef]
  30. Mohamed, Z.; El-Koussi, N.A.; Mahfouz, N.M.; Youssef, A.F.; Jaleel, G.A.A.; Shouman, S.A. Cu (I) catalyzed alkyne-azide 1, 3-dipolar cycloaddition (CuAAC): Synthesis of 17α-[1-(substituted phenyl)-1,2,3-triazol-4-yl]-19-nor-testosterone-17β-yl acetates targeting progestational and antipro-liferative activities. Eur. J. Med. Chem. 2015, 97, 75–82. [Google Scholar] [CrossRef]
  31. Kadar, Z.; Kovacs, D.; Frank, E.; Schneider, G.; Huber, J.; Zupko, I.; Bartok, T.; Wolfling, J. Synthesis and in vitro antiproliferative activity of novel androst-5-ene triazolyl and tetrazolyl derivatives. Molecules 2011, 16, 4786–4806. [Google Scholar] [CrossRef] [PubMed]
  32. Molnar, J.; Frank, E.; Minorics, R.; Kadar, Z.; Ocsovszki, I.; Schonecker, B.; Wolfling, J.; Zupko, I. A click approach to novel D-ring-substituted 16α-triazolylestrone derivatives and characterization of their antiproliferative properties. PLoS ONE 2015, 10, e0118104. [Google Scholar] [CrossRef] [Green Version]
  33. Kadar, Z.; Molnar, J.; Schneider, G.; Zupko, I.; Frank, E. A facile ‘click’approach to novel 15β-triazolyl-5α-androstane derivatives, and an evaluation of their antiproliferative activities in vitro. Bioorg. Med. Chem. 2012, 20, 1396–1402. [Google Scholar] [CrossRef] [PubMed]
  34. Kadar, Z.; Baji, A.; Zupko, I.; Bartok, T.; Wolfling, J.; Frank, E. Efficient approach to novel 1α-triazolyl-5α-androstane derivatives as potent antiproliferative agents. Org. Biomol. Chem. 2011, 9, 8051–8057. [Google Scholar] [CrossRef] [PubMed]
  35. Kadar, Z.; Frank, E.; Schneider, G.; Molnar, J.; Zupko, I.; Koti, J.; Schonecker, B.; Wolfling, J. Efficient synthesis of novel A-ring-substituted 1, 2, 3-triazolylcholestane derivatives via catalytic azide-alkyne cycloaddition. Arkivoc 2012, 3, 279–296. [Google Scholar] [CrossRef]
  36. Solum, E.J.; Vik, A.; Hansen, T.V. Synthesis, cytotoxic effects and tubulin polymerization inhibition of 1,4-disubstituted 1,2,3-triazole analogs of 2-methoxyestradiol. Steroids 2014, 87, 46–53. [Google Scholar] [CrossRef]
  37. Banday, A.H.; Shameem, S.A.; Gupta, B.; Kumar, H.S. D-ring substituted 1,2,3-triazolyl 20-keto pregnenanes as potential anticancer agents: Synthesis and biological evaluation. Steroids 2010, 75, 801–804. [Google Scholar] [CrossRef]
  38. Navacchia, M.L.; Marchesi, E.; Perrone, D. Bile acid conjugates with anticancer activity: Most recent research. Molecules 2021, 26, 25. [Google Scholar] [CrossRef]
  39. Navacchia, M.L.; Marchesi, E.; Mari, L.; Chinaglia, N.; Gallerani, E.; Gavioli, R.; Capobianco, M.L.; Perrone, D. Rational Design of Nucleoside–Bile Acid Conjugates Incorporating a Triazole Moiety for Anticancer Evaluation and SAR Exploration. Molecules 2017, 22, 1710. [Google Scholar] [CrossRef] [Green Version]
  40. Perrone, D.; Bortolini, O.; Fogagnolo, M.; Marchesi, E.; Mari, L.; Massarenti, C.; Navacchia, M.L.; Sforza, F.; Varani, K.; Capobianco, M.L. Synthesis and in vitro cytotoxicity of deoxyadenosine–bile acid conjugates linked with 1,2,3-triazole. New J. Chem. 2013, 37, 3559–3567. [Google Scholar] [CrossRef]
  41. Agarwal, D.S.; Krishna, V.S.; Sriram, D.; Yogeeswari, P.; Sakhuja, R. Clickable conjugates of bile acids and nucleosides: Synthesis, characterization, in vitro anticancer and antituberculosis studies. Steroids 2018, 139, 35–44. [Google Scholar] [CrossRef] [PubMed]
  42. Agarwal, D.S.; Singh, R.P.; Lohitesh, K.; Jha, P.N.; Chowdhury, R.; Sakhuja, R. Synthesis and evaluation of bile acid amides of α-cyanostilbenes as anticancer agents. Mol. Divers. 2018, 22, 305–321. [Google Scholar] [CrossRef] [PubMed]
  43. Agarwal, D.S.; Anantaraju, H.S.; Sriram, D.; Yogeeswari, P.; Nanjegowda, S.H.; Mallu, P.; Sakhuja, R. Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. Steroids 2016, 107, 87–97. [Google Scholar] [CrossRef] [PubMed]
  44. Vatmurge, N.S.; Hazra, B.G.; Pore, V.S.; Shirazi, F.; Deshpande, M.V.; Kadreppa, S.; Chattopadhyay, S.; Gonnade, R.G. Synthesis and biological evaluation of bile acid dimers linked with 1, 2, 3-triazole and bis-β-lactam. Org. Biomol. Chem. 2008, 6, 3823–3830. [Google Scholar] [CrossRef]
  45. Jarrahpour, A.; Fathi, J.; Mimouni, M.; Hadda, T.; Sheikh, J.; Chohan, Z.; Parvez, A. Petra, osiris and molinspiration (POM) together as a successful support in drug design: Antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med. Chem. Res. 2012, 21, 1984–1990. [Google Scholar] [CrossRef]
  46. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714–3717. [Google Scholar] [CrossRef]
  47. Gündüz, M.G.; Uğur, S.B.; Güney, F.; Özkul, C.; Krishna, V.S.; Kaya, S.; Sriram, D.; Doğan, S.D. 1,3-Disubstitutedureaderivatives: Synthesis, antimicrobial activity evaluation and in silico studies. Bioorg. Chem. 2020, 102, 2020. [Google Scholar] [CrossRef]
  48. Bartzatt, R.; Donigan, L. Applying pattern recognition methods to analyze the molecular properties of a homologous series of nitrogen mustard agents. AAPS PharmSciTech 2006, 7, 35. [Google Scholar] [CrossRef]
  49. Hao, T.; Ling, Y.; Wu, M.; Shen, Y.; Gao, Y.; Liang, S.; Gao, Y.; Qian, S. Enhanced oral bioavailability of docetaxel in rats combined with myricetin: In situ and in vivo evidences. Eur. J. Pharm. Sci. 2017, 101, 71–79. [Google Scholar] [CrossRef]
  50. Sharma, S.; Mazumdar, S.; Italiya, K.S.; Date, T.; Mahato, R.I.; Mittal, A.; Chitkara, D. Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery. Mol. Pharm. 2018, 15, 2391–2402. [Google Scholar] [CrossRef]
  51. Italiya, K.S.; Mazumdar, S.; Sharma, S.; Chitkara, D.; Mahato, R.I.; Mittal, A. Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. Nanomedicine 2019, 15, 175–187. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 05741 g001 550
Figure 1. Representative examples of triazole-derived steroids and bile acids as anticancer agents.
Figure 1. Representative examples of triazole-derived steroids and bile acids as anticancer agents.
Molecules 26 05741 g001
Molecules 26 05741 sch001 550
Scheme 1. Synthesis of bile-acid-appended triazolyl aryl ketones.
Scheme 1. Synthesis of bile-acid-appended triazolyl aryl ketones.
Molecules 26 05741 sch001
Molecules 26 05741 g002 550
Figure 2. Selective correlations based on 1H,13C-HMBC spectrum of 6aa.
Figure 2. Selective correlations based on 1H,13C-HMBC spectrum of 6aa.
Molecules 26 05741 g002
Molecules 26 05741 g003 550
Figure 3. Apoptosis assay of 6af and 6cf in MCF-7 and 4T1 cells. (a,b) Flow cytometry plots for apoptosis in MCF-7 cells treated with 6af and 6cf, respectively. (c,d) Flow cytometry plots for apoptosis in 4T1 cells treated with 6af and 6cf, respectively. Upper left (necrotic cells), lower left (live cells), lower right (early apoptotic cells) and upper right (late apoptotic cells). (e) Graph showing the apoptosis (%) induced by 6af and 6cf in MCF-7 and 4T1 cells.
Figure 3. Apoptosis assay of 6af and 6cf in MCF-7 and 4T1 cells. (a,b) Flow cytometry plots for apoptosis in MCF-7 cells treated with 6af and 6cf, respectively. (c,d) Flow cytometry plots for apoptosis in 4T1 cells treated with 6af and 6cf, respectively. Upper left (necrotic cells), lower left (live cells), lower right (early apoptotic cells) and upper right (late apoptotic cells). (e) Graph showing the apoptosis (%) induced by 6af and 6cf in MCF-7 and 4T1 cells.
Molecules 26 05741 g003
Molecules 26 05741 g004 550
Figure 4. The pharmacokinetic profile for 6cf in rat plasma after i.v. bolus at dose of 10 mg/kg administration to rat.
Figure 4. The pharmacokinetic profile for 6cf in rat plasma after i.v. bolus at dose of 10 mg/kg administration to rat.
Molecules 26 05741 g004
Table
Table 1. 1H and 13C NMR assignments for the representative proton/carbon signals of 6aa.
Table 1. 1H and 13C NMR assignments for the representative proton/carbon signals of 6aa.
S. No.Labeling1H NMR13C NMR
1.180.57 (s, 3H)12.8
2.190.80 (s, 3H)23.1
3.210.92 (d, J = 6.2 Hz, 3H)17.4
4.33.17 (d, J = 5.1 Hz, 1H)70.9
5.73.61 (brs, 1H)66.7
6.123.78 (d, J = 3.8 Hz, 1H)71.5
7.OH4.33 (d, J = 4.3 Hz, 1H)-
8.OH4.12 (d, J = 3.8 Hz, 1H)-
9.OH4.01 (d, J = 3.3 Hz, 1H)-
10.25 (COO-CH2)5.18 (s, 2H)57.5
11.28 (N-CH2)6.20 (s, 2H)56.3
12.27 (Triazole-H)8.11 (s, 1H)126.9
13.24 (COO)-173.6
14.29 (CO)-192.5
Table
Table 2. In vitro cytotoxicity of compounds (6aa–6df) against two different cancer cell lines and normal human kidney cell line.
Table 2. In vitro cytotoxicity of compounds (6aa–6df) against two different cancer cell lines and normal human kidney cell line.
Com. No.% Cell Viability at 10 µMmilog P dTPSA e% ABS fDrug-Likeness Score
MCF-7 a4T1 bHEK 293 c
6aa77.3274.3286.084.54134.7862.500.75
6ba91.9097.8188.925.45114.5569.480.65
6ca92.0685.1690.133.89137.5761.530.69
6da91.2099.5697.864.81117.3468.510.60
6ab57.3572.9387.634.99134.7862.500.82
6bb67.6085.6989.175.90114.5569.480.72
6cb61.8696.7486.004.34137.5761.530.75
6db78.6953.6789.435.26117.3468.510.66
6ac55.5980.0287.884.59144.0159.310.98
6bc69.6268.4090.775.51123.7866.290.89
6cc95.3656.7996.753.95146.8158.350.96
6dc68.5264.9286.534.87126.5865.320.88
6ad66.4847.7086.794.70134.7862.501.07
6bd79.6252.3589.375.62114.5569.480.97
6cd88.7270.6597.514.06137.5761.531.01
6dd73.7689.9081.614.97117.3468.510.92
6ae79.6258.9296.215.21134.7862.501.14
6be68.5276.0188.376.13114.5569.481.05
6ce69.1650.5992.694.57137.5761.531.09
6de86.8562.8990.455.49117.3468.501.01
6af26.5255.9188.205.34134.7862.500.94
6bf44.4360.8686.826.26114.5569.480.85
6cf37.5349.2787.824.70137.5761.530.88
6df86.4548.3893.465.62117.3468.510.79
DTX g46.4756.88-----
a Human breast adenocarcinoma, b Mouse mammary carcinoma, c Human embryonic kidney 293 cells, d Logarithm of compound partition coefficient between n-octanol and water, e Topological polar surface area, f Percentage absorption calculated using the formula %ABS = 109 − (0.345 × TPSA), g Docetaxel.
Table
Table 3. IC50 (µM) values of the active compounds in two different cancer cell lines.
Table 3. IC50 (µM) values of the active compounds in two different cancer cell lines.
CompoundIC50 (µM)
MCF-7 a4T1 b
6af2.61 ± 0.7012.84 ± 1.80
6bf18.26 ± 1.489.68 ± 1.59
6cf5.71 ± 1.008.76 ± 1.29
DTX9.46 ± 0.9813.85 ± 1.07
a Human breast adenocarcinoma, b Mouse mammary carcinoma.
Table
Table 4. The non-compartmental pharmacokinetic parameters for 6cf in rat plasma after i.v. bolus at dose of 10 mg/kg administration to rat.
Table 4. The non-compartmental pharmacokinetic parameters for 6cf in rat plasma after i.v. bolus at dose of 10 mg/kg administration to rat.
Parameters6cf (Mean ± SEM)
Initial Concentration, C0 (ng/mL)1752.69 ± 66.52
Half-Life, t1/2 (h)5.63 ± 0.539
Elimination Rate Constant, Ke (1/h)0.13 ± 0.01
Area Under the Curve (0 to 12 h), AUC0–last (ng.h/mL)1995.306 ± 87.43
Area Under the Curve (0 to infinity), AUC0–∞ (ng.h/mL)2690.50 ± 113.20
Area Under the First Moment Curve (0 to 12 h), AUMC0–last (ng.h/mL)8155.94 ± 311.78
Area Under the First Moment Curve (0 to infinity), AUMC0–∞ (ng.h/mL)22276.39 ± 2023.334
Mean Residence Time, MRT (h)8.47 ± 0.96
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Agarwal, D.S.; Mazumdar, S.; Italiya, K.S.; Chitkara, D.; Sakhuja, R. Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats. Molecules 2021, 26, 5741. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26195741

AMA Style

Agarwal DS, Mazumdar S, Italiya KS, Chitkara D, Sakhuja R. Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats. Molecules. 2021; 26(19):5741. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26195741

Chicago/Turabian Style

Agarwal, Devesh S., Samrat Mazumdar, Kishan S. Italiya, Deepak Chitkara, and Rajeev Sakhuja. 2021. "Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats" Molecules 26, no. 19: 5741. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26195741

Article Metrics

Back to TopTop